Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Trevena Yönetim

Yönetim kriter kontrolleri 2/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

Carrie Bourdow

İcra Kurulu Başkanı

US$1.7m

Toplam tazminat

CEO maaş yüzdesi	40.9%
CEO görev süresi	6yrs
CEO sahipliği	0.2%
Yönetim ortalama görev süresi	6yrs
Yönetim Kurulu ortalama görev süresi	10.3yrs

Son yönetim güncellemeleri

Recent updates

CEO Tazminat Analizi

Carrie Bourdow'un ücretlendirmesi Trevena'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Jun 30 2024	n/a	n/a	-US$37m
Mar 31 2024	n/a	n/a	-US$40m
Dec 31 2023	US$2m	US$682k	-US$40m
Sep 30 2023	n/a	n/a	-US$31m
Jun 30 2023	n/a	n/a	-US$38m
Mar 31 2023	n/a	n/a	-US$45m
Dec 31 2022	US$1m	US$656k	-US$54m
Sep 30 2022	n/a	n/a	-US$61m
Jun 30 2022	n/a	n/a	-US$59m
Mar 31 2022	n/a	n/a	-US$58m
Dec 31 2021	US$2m	US$637k	-US$52m
Sep 30 2021	n/a	n/a	-US$50m
Jun 30 2021	n/a	n/a	-US$41m
Mar 31 2021	n/a	n/a	-US$33m
Dec 31 2020	US$3m	US$613k	-US$29m
Sep 30 2020	n/a	n/a	-US$24m
Jun 30 2020	n/a	n/a	-US$27m
Mar 31 2020	n/a	n/a	-US$25m
Dec 31 2019	US$2m	US$563k	-US$25m
Sep 30 2019	n/a	n/a	-US$26m
Jun 30 2019	n/a	n/a	-US$22m
Mar 31 2019	n/a	n/a	-US$27m
Dec 31 2018	US$2m	US$418k	-US$31m
Sep 30 2018	n/a	n/a	-US$38m
Jun 30 2018	n/a	n/a	-US$49m
Mar 31 2018	n/a	n/a	-US$60m
Dec 31 2017	US$1m	US$341k	-US$72m

Tazminat ve Piyasa: Carrie 'nin toplam tazminatı ($USD 1.66M ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 677.23K ).

Tazminat ve Kazançlar: Carrie şirketinin tazminatı, şirket kârsız olduğu sürece artırıldı.

CEO

Carrie Bourdow (61 yo)

6yrs

Görev süresi

US$1,664,855

Tazminat

Ms. Carrie L. Bourdow has been Chief Executive Officer, President and Director at Trevena, Inc. since October 01, 2018 and serves as its Chairman since November 09, 2023. Ms. Bourdow served as an Executive...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Carrie Bourdow	President	6yrs	US$1.66m	0.24% $ 4.4k
Barry Shin	Executive VP	5.3yrs	US$1.01m	0.15% $ 2.7k
Mark Demitrack	Senior VP & Chief Medical Officer	6.4yrs	US$1.03m	0.23% $ 4.1k
Howard Rockman	Scientific Founder	no data	Veri yok	Veri yok
Michael Catalano	Vice President of Marketing	6.7yrs	Veri yok	Veri yok
Robert Yoder	Senior VP	5.8yrs	US$689.16k	0.049% $ 894.6

6.0yrs

Ortalama Görev Süresi

59.5yo

Ortalama Yaş

Deneyimli Yönetim: TRVN 'un yönetim ekibi deneyimli ve deneyimlidir ( 6 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Carrie Bourdow	President	6yrs	US$1.66m	0.24% $ 4.4k
Howard Rockman	Scientific Founder	no data	Veri yok	Veri yok
William Schmidt	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Jason Nunn	Independent Director	11.3yrs	US$76.11k	0.00082% $ 14.9
John LaMattina	Member of the Scientific Advisory Board	15.8yrs	Veri yok	Veri yok
Robert Lefkowitz	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Robert Richard Ruffolo	Member of the Scientific Advisory Board	15.8yrs	Veri yok	Veri yok
Mark H. Corrigan	Independent Director	1.3yrs	US$55.87k	0% $ 0
Anne Phillips	Independent Director	10.8yrs	US$76.11k	0% $ 0
Scott Braunstein	Lead Independent Director	6.1yrs	US$70.11k	0% $ 0
Barbara Yanni	Independent Director	10.3yrs	US$76.58k	0.00023% $ 4.2
Marvin Johnson	Independent Director	3.6yrs	US$61.11k	0% $ 0

10.3yrs

Ortalama Görev Süresi

70yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: TRVN 'in yönetim kurulu deneyimli ve tecrübelidir (ortalama görev süresi 10.3 yıldır).

Trevena Yönetim

Yönetim kriter kontrolleri 2/4

Anahtar bilgiler

Son yönetim güncellemeleri

Trevena, Inc., Annual General Meeting, Jun 13, 2024

Trevena, Inc. Promotion of Barry Shin to the Position of Executive Vice President and Chief Operating Officer

Trevena, Inc. Announces Board Changes

Trevena, Inc. Announces Retirement of Michael Dougherty as A Member of the Board of Directors and as A Member of the Audit Committee, Effective as of September 14, 2023

Trevena, Inc. Appoints Mark Corrigan to Board of Directors

Insufficient new directors

Recent updates

Trevena, Inc.(OTCPK:TRVN) dropped from S&P TMI Index

Trevena, Inc.(OTCPK:TRVN) dropped from NASDAQ Composite Index

Trevena Announces Receipt of Nasdaq Delisting Notification

Trevena Regains Compliance with the Minimum Bid Price Requirement from Nasdaq

New major risk - Share price stability

New major risk - Revenue and earnings growth

Second quarter 2024 earnings released: US$0.23 loss per share (vs US$0.69 loss in 2Q 2023)

Trevena, Inc. Announces Preclinical TRV045 Data Providing Insight Into Novel Mechanism of Analgesic Effect in Chronic Neuropathic Pain Model and Demonstrating Statistically Significant Anti-Seizure Activity in Epilepsy Models

First quarter 2024 earnings released: US$0.36 loss per share (vs US$0.81 loss in 1Q 2023)

Nasdaq Hearings Panel Grants Trevena an Extension Until August 28, 2024 to Regain Compliance with the Nasdaq Continued Listing Requirements, Including the Minimum Bid Price Requirement and Equity Standard Requirement

Trevena, Inc., Annual General Meeting, Jun 13, 2024

New major risk - Revenue and earnings growth

Full year 2023 earnings: EPS and revenues miss analyst expectations

No longer forecast to breakeven

New major risk - Market cap size

Trevena, Inc. Promotion of Barry Shin to the Position of Executive Vice President and Chief Operating Officer

Trevena, Inc. announced that it expects to receive $1.945934 million in funding

Trevena, Inc. announced that it expects to receive $1.945934 million in funding

Trevena, Inc. announced that it expects to receive $1.945934 million in funding

Trevena, Inc. Announces Acceptance of Abstract Examining the Use of Olinvyk in Patients with Acute Burn Injuries

New major risk - Revenue and earnings growth

Consensus EPS estimates fall by 28%, revenue upgraded

Trevena, Inc. Announces Board Changes

Trevena, Inc. to Report Q3, 2023 Results on Nov 14, 2023

New major risk - Revenue and earnings growth

Trevena, Inc. Announces Completion of Initial Analysis of Olinvyk Continuous Respiratory Monitoring Data from Volition Study

Trevena, Inc. Announces Retirement of Michael Dougherty as A Member of the Board of Directors and as A Member of the Audit Committee, Effective as of September 14, 2023

Trevena, Inc. Announces Preliminary TRV045 Data from Two Proof-Of-Concept Studies Evaluating S1pr Mechanism of Action and CNS Target Engagement

Trevena Receives Non-Compliance Notice From Nasdaq Stock Market

Consensus revenue estimates increase by 725%

New major risk - Market cap size

Trevena, Inc. Appoints Mark Corrigan to Board of Directors

Trevena, Inc. Announces New Topline OLINVYK Data Highlighting Reduced Cost Per Admission from Artemis Real-World Outcomes Study

New major risk - Market cap size

Trevena Regains Compliance with the Minimum Bid Price Requirement under Nasdaq Listing Rule 5550(a)(2)

Trevena, Inc. to Report Q1, 2023 Results on May 15, 2023

Price target decreased by 39% to US$17.00

Trevena Announces Publication of OLINVYK Respiratory Physiology Study in ANESTHESIOLOGY

Trevena, Inc. Enrolls First Subject in TRV045 Proof-of-Concept Trial Evaluating S1PR Mechanism of Action and Target Engagement

Trevena Regains Compliance with Nasdaq Listing Requirements

Price target decreased to US$28.67

Insufficient new directors

Trevena Announces Completion of Phase 1 Study for Trv045, Novel S1p Receptor Modulator

Trevena, Inc. to Report Q3, 2022 Results on Nov 09, 2022

Trevena Announces OLINVYK Poster Presentation at the ANESTHESIOLOGY® 2022 Annual Meeting

Consensus forecasts updated

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Trevena Q2 2022 Earnings Preview

Trevena, Inc. to Report Q2, 2022 Results on Aug 11, 2022

Trevena Announces Positive Topline OLINVYK Cognitive Function Data and Provides General Business Update

Trevena slides on $2M preferred stock offering

Trevena (NASDAQ:TRVN) Will Have To Spend Its Cash Wisely

Trevena Gets an Additional 180 Days to Get Listing Compliance

Consensus revenue estimates fall by 36%

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Trevena, Inc., Annual General Meeting, Jun 09, 2022

Insufficient new directors

Trevena, Inc. Receives Notice to Cease Enrollment for TRV027 as Part of the ACTIV-4 Host Tissue Platform

Trevena, Inc. Announces Results from Pfound D Sedation, Respiratory Depression, Coma, and Death May Result from E Concomitant Use of Olinvyk

Consensus forecasts updated

Trevena, Inc. to Report Q4, 2021 Results on Mar 31, 2022

Is Trevena (NASDAQ:TRVN) In A Good Position To Deliver On Growth Plans?

Price target decreased to US$4.67

Insufficient new directors

Trevena, Inc. Announces Submission of New Drug Application in China for OLINVYK® by its Partner Jiangsu Nhwa Pharmaceutical

Trevena, Inc. Announces Advancement of TRV045 Into Clinical Development for Diabetic Neuropathic Pain

Trevena Offers An Enticing Risk-Reward At These Prices

Trevena Announces Wake Forest Baptist Health Joining OLINVYK® Clinical Outcomes Study

Trevena: Remaining Patient After A Disappointing Q2 Earnings